Among these genes, those associated with an increased risk of GC development included LCOR, VPS26A, KRR1, ARHGAP21, ECHDC1, UBE2D1, MTFR1, and ETV7, whereas the gene associated with a decreased risk of GC development was PARD6G. Previous studies have shown that high expression of LCOR in GC is independently associated with poor prognosis, suggesting that it may be a common potential therapeutic target. Here, UBE2D1 is linked to gastric cancer.